E14a2 <i>BCR-ABL1</i> transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy.

Claudiani, Simone, Apperley, Jane F, Gale, Robert Peter, Clark, Richard ORCID: 0000-0002-1261-3299, Szydlo, Richard ORCID: 0000-0003-1102-8298, Deplano, Simona, Palanicawandar, Renuka, Khorashad, Jamshid, Foroni, Letizia and Milojkovic, Dragana (2017) E14a2 <i>BCR-ABL1</i> transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy. Haematologica, 102 (8). e297-e299.

Text
Claudiani S et al. - Manuscript Haematologica.pdf - Author Accepted Manuscript
Download (718kB) | Preview

Official URL: http://dx.doi.org/10.3324/haematol.2017.168740

Item Type:	Article
Uncontrolled Keywords:	Humans, Fusion Proteins, bcr-abl, RNA, Neoplasm, Protein Kinase Inhibitors, Withholding Treatment, Remission Induction, Adult, Aged, Aged, 80 and over, Middle Aged, Female, Male, Protein-Tyrosine Kinases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Depositing User:	Symplectic Admin
Date Deposited:	23 May 2019 15:33
Last Modified:	19 Jan 2023 00:43
DOI:	10.3324/haematol.2017.168740
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3042655